Executives from Atlantic Research Group discuss the importance of CRAs in rare disease clinical trials.
Paul Bishop and Lyle Camblos
Advertisement
Paul Bishop is CEO, Atlantic Research Group (ARG), and can be reached at pbishop@atlanticresearchgroup.com Lyle Camblos is Managing Partner, Atlantic Research Group (ARG) and can be reached at lcamblos@atlanticresearchgroup.com
Articles by Paul Bishop and Lyle Camblos
Advertisement
Latest Updated Articles
- The Value of Empowered CRAs in Rare Disease Studies
Published: August 2nd 2017 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Bringing Clinical Trials Into the Digital Era with eConsent
2
ACT Brief: AI Innovations, Vision Trial Breakthroughs, and a Major Industry Acquisition
3
Global Breast Cancer Trials Show Progress in Diversity, But Gaps Remain
4
ACT Brief: Digital Consent, Global Diversity, and Clinical Setbacks Shape Today’s Clinical Research Landscape
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
